Seeking Alpha

BioTime (BTX +1.6%) has developed a method to produce seven distinct types of cartilage, bone,...

BioTime (BTX +1.6%) has developed a method to produce seven distinct types of cartilage, bone, and tendon cells from human embryonic stem cells using the company's PureStem technology. A lab study showed that BioTime's cells, which can be manufactured on an industrial scale, are "progenitors to diverse skeletal tissues of the human body." BioTime expects to file a request for a Phase I trial in Q1. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs